Pharma/PBMs

HR leaders need a clearer understanding of how pharmacy benefits actually work and what increasing calls for transparency could mean for their responsibilities going forward.

The ever-expanding popularity of GLP-1 drugs for weight loss is challenging employers to balance access and cost.

"While many Americans are satisfied with their coverage options for 2026, many are facing significant cost increases and less rich benefits," said Derrick Duke, CEO of eHealth.

The proposed change could save 7,049 HRA and ICHRA sponsors from the notice requirements.

The survey also noted that 34% of firms require lifestyle or clinical support programs in order for employees to receive GLP-1 agonists for weight loss.

Medical costs are up 6%, drug costs are up 10%, and there are "no signs this trend will slow," Brown & Brown's CEO says.